Lovastatin Tablet
Product Images NDC 50090-3881

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Lovastatin (NDC 50090-3881). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image (Lbl500903881)

Lovastatin 20 mg oral tablets packaging label from A-S Medication Solutions, displaying the product NDC 50090-3881. The label indicates storage instructions to keep the product at 68 to 77 degrees Fahrenheit and protect it from light. The package contains 30 tablets in a bottle.*

FDA Label Image

Structural Formula (Lov00 0004 01)

Chemical structure of lovastatin shown in a detailed molecular diagram, illustrating its specific atomic and bond arrangement.*

FDA Label Image

Table I (Lov00 0004 02)

A data table titled 'The Effect of Other Drugs on Lovastatin Exposure When Both Were Co-administered.' It summarizes the number of subjects, dosing of coadministered drugs or grapefruit juice, dosing of lovastatin, and Area Under the Curve (AUC) ratios for lovastatin with and without the coadministered drugs. It includes drugs such as Gemfibrozil, Itraconazole, Grapefruit Juice (high and low dose), Cyclosporine, and Diltiazem with corresponding dosing and effects on lovastatin exposure.*

FDA Label Image

Figure 1 (Lov00 0004 03)

A Kaplan-Meier survival curve titled 'Acute Major Coronary Events (Primary Endpoint)' comparing Lovastatin with placebo over six years. The y-axis shows the proportion of participants without event, and the x-axis shows years of follow-up, depicting a lower event rate in the Lovastatin group with a noted 37% risk reduction (p < 0.001).*

FDA Label Image

Table Vii (Lov00 0005 04)

Data table listing drug interactions associated with increased risk of myopathy/rhabdomyolysis with lovastatin. It includes interacting agents such as strong CYP3A4 inhibitors and their prescribing recommendations, including contraindications and dosage limits for coadministration with lovastatin, as well as advice to avoid grapefruit juice.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.